JP2008515890A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008515890A5 JP2008515890A5 JP2007535709A JP2007535709A JP2008515890A5 JP 2008515890 A5 JP2008515890 A5 JP 2008515890A5 JP 2007535709 A JP2007535709 A JP 2007535709A JP 2007535709 A JP2007535709 A JP 2007535709A JP 2008515890 A5 JP2008515890 A5 JP 2008515890A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- medicament according
- exposure
- medicament
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 123
- 239000003795 chemical substances by application Substances 0.000 claims 23
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 20
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 20
- 150000003431 steroids Chemical group 0.000 claims 19
- 239000003018 immunosuppressive agent Substances 0.000 claims 16
- 206010047115 Vasculitis Diseases 0.000 claims 13
- 229940125721 immunosuppressive agent Drugs 0.000 claims 13
- 229940127089 cytotoxic agent Drugs 0.000 claims 10
- 238000004519 manufacturing process Methods 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 7
- 230000001086 cytosolic effect Effects 0.000 claims 6
- 239000002254 cytotoxic agent Substances 0.000 claims 6
- 231100000599 cytotoxic agent Toxicity 0.000 claims 6
- 102220517543 Calcium uniporter protein, mitochondrial_S92A_mutation Human genes 0.000 claims 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 4
- 229940123038 Integrin antagonist Drugs 0.000 claims 4
- 102220556084 Myeloid cell surface antigen CD33_N100A_mutation Human genes 0.000 claims 4
- 102220475559 Radial spoke head 1 homolog_D56A_mutation Human genes 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 4
- 229960004397 cyclophosphamide Drugs 0.000 claims 4
- 239000000430 cytokine receptor antagonist Substances 0.000 claims 4
- 229940088597 hormone Drugs 0.000 claims 4
- 239000005556 hormone Substances 0.000 claims 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 4
- 102220241870 rs761659830 Human genes 0.000 claims 4
- 229960003444 immunosuppressant agent Drugs 0.000 claims 3
- 230000001861 immunosuppressant effect Effects 0.000 claims 3
- -1 integrin antagonist Substances 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 2
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 claims 2
- 206010018691 Granuloma Diseases 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims 2
- 230000002482 anti-endothelial effect Effects 0.000 claims 2
- 230000003460 anti-nuclear Effects 0.000 claims 2
- 230000003356 anti-rheumatic effect Effects 0.000 claims 2
- 239000003435 antirheumatic agent Substances 0.000 claims 2
- 229960002170 azathioprine Drugs 0.000 claims 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 229960004630 chlorambucil Drugs 0.000 claims 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229940109239 creatinine Drugs 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 239000002988 disease modifying antirheumatic drug Substances 0.000 claims 2
- 229960000890 hydrocortisone Drugs 0.000 claims 2
- 229960000681 leflunomide Drugs 0.000 claims 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 229960004584 methylprednisolone Drugs 0.000 claims 2
- 206010063344 microscopic polyangiitis Diseases 0.000 claims 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 2
- 229960004866 mycophenolate mofetil Drugs 0.000 claims 2
- 229960005205 prednisolone Drugs 0.000 claims 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 2
- 229960004618 prednisone Drugs 0.000 claims 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61610404P | 2004-10-05 | 2004-10-05 | |
| PCT/US2005/034647 WO2006041680A2 (en) | 2004-10-05 | 2005-09-28 | Method for treating vasculitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008515890A JP2008515890A (ja) | 2008-05-15 |
| JP2008515890A5 true JP2008515890A5 (https=) | 2008-11-06 |
Family
ID=36148785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007535709A Pending JP2008515890A (ja) | 2004-10-05 | 2005-09-28 | 血管炎の治療方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20060110387A1 (https=) |
| EP (1) | EP1812060A2 (https=) |
| JP (1) | JP2008515890A (https=) |
| KR (1) | KR20070100228A (https=) |
| CN (1) | CN101087807A (https=) |
| AR (1) | AR052219A1 (https=) |
| AU (1) | AU2005294666A1 (https=) |
| BR (1) | BRPI0516297A (https=) |
| CA (1) | CA2580271A1 (https=) |
| GT (1) | GT200500276A (https=) |
| IL (1) | IL181922A0 (https=) |
| NO (1) | NO20072312L (https=) |
| PA (1) | PA8647601A1 (https=) |
| PE (1) | PE20060934A1 (https=) |
| RU (1) | RU2411956C2 (https=) |
| SG (1) | SG165344A1 (https=) |
| SV (1) | SV2006002256A (https=) |
| TW (1) | TW200628169A (https=) |
| WO (1) | WO2006041680A2 (https=) |
| ZA (2) | ZA200702335B (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA01011279A (es) * | 1999-05-07 | 2002-07-02 | Genentech Inc | Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b. |
| CA2422076A1 (en) * | 2000-09-18 | 2002-03-21 | Idec Pharmaceutical Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| ES2672640T3 (es) | 2003-11-05 | 2018-06-15 | Roche Glycart Ag | Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas |
| HRP20140338T1 (hr) | 2005-07-25 | 2014-06-20 | Emergent Product Development Seattle, Llc | Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20 |
| EP1878747A1 (en) | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Glyco-engineered antibodies |
| NZ583019A (en) | 2007-07-31 | 2011-05-27 | Regeneron Pharma | Human antibodies to human cd20 and method of using thereof |
| EP2365003A1 (en) | 2008-04-11 | 2011-09-14 | Emergent Product Development Seattle, LLC | CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
| US20110152223A1 (en) * | 2008-08-22 | 2011-06-23 | Junichi Hirahashi | Therapeutic agent for anca-related vasculitis |
| TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
| WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| US8728730B2 (en) * | 2009-09-03 | 2014-05-20 | Genentech, Inc. | Methods for treating, diagnosing, and monitoring rheumatoid arthritis |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| TW201129384A (en) | 2010-02-10 | 2011-09-01 | Immunogen Inc | CD20 antibodies and uses thereof |
| KR20130050952A (ko) | 2010-06-16 | 2013-05-16 | 브루스 챈들러 메이 | 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도 |
| BR112013021725A2 (pt) | 2011-02-28 | 2016-11-01 | Genentech Inc | marcadores biológicos e métodos para prever resposta aos antagonistas de células b |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| MX382776B (es) | 2013-03-13 | 2025-03-13 | Inflammatory Response Res Inc | Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica. |
| RU2015134423A (ru) | 2013-03-13 | 2017-04-26 | Инфламматори Респонс Ресёрч, Инк. | Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств |
| WO2014164285A2 (en) * | 2013-03-13 | 2014-10-09 | Inflammatory Response Research, Inc. | Use of levocetirizine and montelukast in the treatment of vasculitis |
| WO2015197194A2 (en) * | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| WO2016044095A1 (en) | 2014-09-15 | 2016-03-24 | Inflammatory Response Research, Inc. | Levocetirizine and montelukast in the treatment of inflammation mediated conditions |
| RS60739B1 (sr) | 2014-11-17 | 2020-09-30 | Regeneron Pharma | Postupci za lečenje tumora upotrebom cd3xcd20 bispecifičnog antitela |
| CN105688208A (zh) * | 2016-03-04 | 2016-06-22 | 刘文霞 | 一种用于治疗视网膜血管炎的复方颗粒及其制备方法 |
| WO2018071524A1 (en) * | 2016-10-11 | 2018-04-19 | The University Of North Carolina At Chapel Hill | Gene-specific dna methylation changes predict relapse/remission in anca-associated vasculitis patients |
| AU2019217870A1 (en) * | 2018-02-07 | 2020-08-27 | Insmed Incorporated | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating ANCA associated vasculitides |
| EP3755346B1 (en) | 2018-02-23 | 2024-12-04 | Duke University | Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants |
| US12364715B2 (en) | 2018-02-23 | 2025-07-22 | Enzyvant Therapeutics Gmbh | Methods of determining the suitability of cultured thymus tissue for implantation into humans and associated methods of use |
| US11819520B2 (en) | 2018-02-23 | 2023-11-21 | Duke University | Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants |
| RS66543B1 (sr) | 2018-08-31 | 2025-03-31 | Regeneron Pharma | Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitela |
| EP3669888B1 (en) | 2018-12-20 | 2025-09-24 | Gambro Lundia AB | Extracorporeal devices for methods for treating diseases associated with anti-neutrophil cytoplasmic antibodies |
| WO2021236518A1 (en) | 2020-05-19 | 2021-11-25 | IRR, Inc. | Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof |
| KR20240102971A (ko) | 2021-11-16 | 2024-07-03 | 제넨테크, 인크. | 모수네투주맙을 이용하여 전신 홍반성 루푸스(sle)를 치료하기 위한 방법과 조성물 |
| WO2025007943A1 (zh) * | 2023-07-06 | 2025-01-09 | 荣昌生物制药(烟台)股份有限公司 | 用taci-fc融合蛋白治疗anca相关性血管炎的方法 |
| CN119322175A (zh) * | 2024-10-18 | 2025-01-17 | 武汉塞力斯生物技术有限公司 | 一种血管炎抗体联检试剂盒 |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4690905A (en) * | 1983-11-16 | 1987-09-01 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method for removal of human antibodies to native DNA from serum |
| US6893625B1 (en) * | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5506126A (en) * | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
| US4861579A (en) * | 1988-03-17 | 1989-08-29 | American Cyanamid Company | Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| RU2170256C2 (ru) * | 1991-07-25 | 2001-07-10 | Айдек Фармасьютикалс Корпорейшн | Рекомбинантное антитело, специфичное к cd4, способ его получения и фармацевтическая композиция для лечения псориаза |
| IE922437A1 (en) * | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| ES2136092T3 (es) * | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5573905A (en) * | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US7744877B2 (en) * | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
| MD1367C2 (ro) * | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5601855A (en) * | 1993-08-12 | 1997-02-11 | Schreiber Foods, Inc. | Apparatus for producing shredded cheese |
| US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| ES2251723T3 (es) * | 1994-08-12 | 2006-05-01 | Immunomedics, Inc. | Inmunoconjugados y anticuerpos humanizados especificos para linfoma de celulas b y celulas de leucemia. |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6378442B1 (en) | 1995-07-21 | 2002-04-30 | Siemens Aktiengesellschaft | Car body |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US20010056066A1 (en) * | 1996-07-26 | 2001-12-27 | Smithkline Beecham Corporation | Method of treating immune cell mediated systemic diseases |
| ES2248823T5 (es) | 1996-10-25 | 2011-11-03 | Human Genome Sciences, Inc. | Neutroquina alfa. |
| WO1998026086A1 (en) * | 1996-12-11 | 1998-06-18 | University Of Florida | Novel methods and compositions for treatment of autoimmune diseases |
| AU5705898A (en) | 1996-12-17 | 1998-07-15 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| CA2232743A1 (en) | 1997-04-02 | 1998-10-02 | Smithkline Beecham Corporation | A tnf homologue, tl5 |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ATE296315T1 (de) | 1997-06-24 | 2005-06-15 | Genentech Inc | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
| AU8296098A (en) * | 1997-07-08 | 1999-02-08 | Board Of Regents, The University Of Texas System | Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
| CA2303424A1 (en) | 1997-09-12 | 1999-03-18 | Jurg Tschopp | Kay - a novel immune system protein |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| WO1999033980A2 (en) | 1997-12-30 | 1999-07-08 | Chiron Corporation | Members of tnf and tnfr families |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6528624B1 (en) * | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| CA2340091C (en) * | 1998-08-11 | 2013-02-05 | Idec Pharmaceuticals Corporation | Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody |
| US6224866B1 (en) * | 1998-10-07 | 2001-05-01 | Biocrystal Ltd. | Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors |
| KR20010099788A (ko) * | 1998-11-09 | 2001-11-09 | 케네쓰 제이. 울코트 | Ｂｍｔ 또는 ｐｂｓｃ 이식을 받은 환자의 키메라항-ｃｄ２０ 항체 치료법 |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6897044B1 (en) * | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
| EP1035172A3 (en) * | 1999-03-12 | 2002-11-27 | Fuji Photo Film Co., Ltd. | Azomethine compound and oily magenta ink |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| MXPA01011279A (es) * | 1999-05-07 | 2002-07-02 | Genentech Inc | Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b. |
| CA2375912C (en) * | 1999-06-09 | 2014-03-11 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target b-cells |
| DE19930748C2 (de) * | 1999-07-02 | 2001-05-17 | Infineon Technologies Ag | Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip |
| AU6929100A (en) * | 1999-08-23 | 2001-03-19 | Biocrystal Limited | Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Kyowa Kirin Co., Ltd. | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| RU2305561C2 (ru) * | 1999-11-08 | 2007-09-10 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием антител против cd40l в комбинации с антителами против cd20 и/или химиотерапией и лучевой терапией |
| US20020006404A1 (en) * | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| US20020028178A1 (en) * | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| US20030185796A1 (en) * | 2000-03-24 | 2003-10-02 | Chiron Corporation | Methods of therapy for non-hodgkin's lymphoma |
| AU2001247737A1 (en) * | 2000-03-24 | 2001-10-08 | Chiron Corporation | Methods of therapy for non-hodgkin's lymphoma using a combination of an antibodyto cd20 and interleuking-2 |
| CN1981868A (zh) * | 2000-03-31 | 2007-06-20 | 拜奥根Idec公司 | 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用 |
| CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
| AU5914201A (en) * | 2000-04-25 | 2001-11-07 | Idec Pharma Corp | Intrathecal administration of rituximab for treatment of central nervous system lymphomas |
| CA2411102A1 (en) * | 2000-06-20 | 2001-12-27 | Idec Pharmaceutical Corporation | Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination |
| AU2001270134B2 (en) * | 2000-06-22 | 2006-06-15 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
| CA2422076A1 (en) * | 2000-09-18 | 2002-03-21 | Idec Pharmaceutical Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| NZ526720A (en) * | 2000-12-28 | 2007-11-30 | Altus Pharmaceuticals Inc | Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies |
| US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030103971A1 (en) * | 2001-11-09 | 2003-06-05 | Kandasamy Hariharan | Immunoregulatory antibodies and uses thereof |
| IL157946A0 (en) * | 2001-04-02 | 2004-03-28 | Genentech Inc | Combination therapy |
| EP2180044A1 (en) | 2001-08-03 | 2010-04-28 | GlycArt Biotechnology AG | Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity |
| JP3838890B2 (ja) * | 2001-08-21 | 2006-10-25 | Ｎｅｃエレクトロニクス株式会社 | 半導体集積回路とその設計方法 |
| US7718387B2 (en) * | 2001-09-20 | 2010-05-18 | Board Of Regents, The University Of Texas System | Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| US20040093621A1 (en) * | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| KR101033196B1 (ko) * | 2002-02-14 | 2011-05-09 | 이뮤노메딕스, 인코오포레이티드 | 항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법 |
| US20030180292A1 (en) * | 2002-03-14 | 2003-09-25 | Idec Pharmaceuticals | Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy |
| EA200401325A1 (ru) | 2002-04-09 | 2005-04-28 | Киова Хакко Когио Ко., Лтд. | Клетки с модифицированным геномом |
| US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
| JP4832719B2 (ja) | 2002-04-09 | 2011-12-07 | 協和発酵キリン株式会社 | ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬 |
| US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
| US20030219818A1 (en) * | 2002-05-10 | 2003-11-27 | Bohen Sean P. | Methods and compositions for determining neoplastic disease responsiveness to antibody therapy |
| US7166120B2 (en) | 2002-07-12 | 2007-01-23 | Ev3 Inc. | Catheter with occluding cuff |
| AU2003294210A1 (en) * | 2002-07-31 | 2004-05-04 | Seattle Genetics, Inc | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| CN101928344B (zh) * | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| EP3263596A1 (en) * | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| EP2062916A3 (en) * | 2003-04-09 | 2009-08-19 | Genentech, Inc. | Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor |
| AR044388A1 (es) * | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
| BRPI0412217A (pt) * | 2003-07-29 | 2006-08-22 | Genentech Inc | método de avaliação da eficácia de anticorpo, métodos de imunoterapia, método de detecção de anticorpos neutralizantes a anticorpo terapêutico e método de avaliação da eficácia de antagonista |
| US8147832B2 (en) * | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
| KR20060132554A (ko) * | 2003-08-29 | 2006-12-21 | 제넨테크, 인크. | 안과 질병의 항-ｃｄ２０ 치료 |
| US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
| JPWO2005035778A1 (ja) | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法 |
| ES2672640T3 (es) * | 2003-11-05 | 2018-06-15 | Roche Glycart Ag | Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| JP5254524B2 (ja) * | 2004-11-17 | 2013-08-07 | 株式会社ナチュラレーザ・ワン | 原稿圧着板自動開閉装置及びこの原稿圧着板自動開閉装置を備えた事務機器 |
-
2005
- 2005-09-28 CA CA002580271A patent/CA2580271A1/en not_active Abandoned
- 2005-09-28 SG SG201006432-7A patent/SG165344A1/en unknown
- 2005-09-28 JP JP2007535709A patent/JP2008515890A/ja active Pending
- 2005-09-28 KR KR1020077007778A patent/KR20070100228A/ko not_active Ceased
- 2005-09-28 EP EP05810224A patent/EP1812060A2/en not_active Withdrawn
- 2005-09-28 CN CNA2005800417165A patent/CN101087807A/zh active Pending
- 2005-09-28 AU AU2005294666A patent/AU2005294666A1/en not_active Abandoned
- 2005-09-28 US US11/238,281 patent/US20060110387A1/en not_active Abandoned
- 2005-09-28 RU RU2007116980/15A patent/RU2411956C2/ru not_active IP Right Cessation
- 2005-09-28 ZA ZA200702335A patent/ZA200702335B/xx unknown
- 2005-09-28 WO PCT/US2005/034647 patent/WO2006041680A2/en not_active Ceased
- 2005-09-28 BR BRPI0516297-1A patent/BRPI0516297A/pt not_active IP Right Cessation
- 2005-10-04 PA PA20058647601A patent/PA8647601A1/es unknown
- 2005-10-05 SV SV2005002256A patent/SV2006002256A/es unknown
- 2005-10-05 PE PE2005001180A patent/PE20060934A1/es not_active Application Discontinuation
- 2005-10-05 TW TW094134821A patent/TW200628169A/zh unknown
- 2005-10-05 GT GT200500276A patent/GT200500276A/es unknown
- 2005-10-05 AR ARP050104207A patent/AR052219A1/es not_active Application Discontinuation
-
2006
- 2006-09-28 US US11/536,571 patent/US20070025987A1/en not_active Abandoned
-
2007
- 2007-03-14 IL IL181922A patent/IL181922A0/en unknown
- 2007-05-04 NO NO20072312A patent/NO20072312L/no not_active Application Discontinuation
-
2008
- 2008-05-20 ZA ZA200804339A patent/ZA200804339B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008515890A5 (https=) | ||
| JP2008507555A5 (https=) | ||
| RU2006147253A (ru) | Способ лечения рассеянного склероза | |
| JP2022050618A5 (https=) | ||
| RU2396980C2 (ru) | Способ лечения волчанки | |
| JP2008501712A5 (https=) | ||
| Muntean et al. | Immunosuppression in kidney transplantation | |
| JP2022078265A5 (https=) | ||
| JP2014515036A5 (https=) | ||
| JP2025188073A (ja) | 同種キメラ抗原受容体ｔ細胞投与のための方法および組成物 | |
| JP2020508317A5 (https=) | ||
| RU2007106722A (ru) | Способ лечения синдрома шегрена | |
| JP2021501776A5 (https=) | ||
| RU2006140374A (ru) | Лечение нарушений | |
| JP2018503610A5 (https=) | ||
| JP2022184998A (ja) | 特定の癌の治療のためのラムシルマブとペンブロリズマブとの組み合わせ | |
| CN119053343A (zh) | 抗tim-3抗体与抗pd-1抗体的药物组合 | |
| Siddique et al. | Road to remission: a comprehensive review of therapy in uveitis | |
| CN102215867A (zh) | 疾病治疗用组合物 | |
| CN110678201A (zh) | 抗cd19抗体和维奈托克组合治疗的治疗模式 | |
| CN111973747A (zh) | 用于联合治疗卵巢癌的喹啉衍生物 | |
| Jurgens et al. | The use of conventional disease-modifying anti-rheumatic drugs in established RA | |
| CN120437318A (zh) | 抗体药物偶联物和免疫检查点抑制剂的联合应用 | |
| JPWO2021050645A5 (https=) | ||
| IL312514A (en) | Corticosteroid reduction in treatment with anti-cd38 antibodies |